Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN

(AMGN)
  Report  
Real-time Quote. Real-time Cboe BZX - 08/20 10:35:20 am
205.435 USD   -0.27%
08/14AMGEN : Board of Directors Tours Company Labs in San Francisco
PU
08/14AMGEN : Foundation Honors David Baltimore With Gift to Caltech
PU
08/14AMGEN : Ex-dividend day for
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

New Findings from National Lipid Association Describe Advances in Cardiovascular Diseases and Conditions (The Statin Adverse Treatment Experience Survey: Experience of Patients Reporting Side Effects of Statin Therapy): Cardiovascular Diseases and Conditions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 05:20pm EDT

2019 AUG 14 (NewsRx) -- By a News Reporter-Staff News Editor at Disease Prevention Daily -- A new study on Cardiovascular Diseases and Conditions is now available. According to news reporting originating in Jacksonville, United States, by NewsRx journalists, research stated, “It is important to understand patients’ experiences of statin-associated adverse effects to potentially identify those at risk for stopping treatment. The goal of the STatin Adverse Treatment Experience survey was to describe patients’ experiences after reporting recent statin-associated adverse event and identify opportunities to improve adherence and outcomes.”

Funders for this research include Amgen Inc., Amgen Inc.

The news reporters obtained a quote from the research from National Lipid Association, “The survey was developed in 3 stages: qualitative item development, pilot evaluation of initial item performance, and quantitative evaluation using a large commercial sample. Respondents with self-reported high cholesterol who had taken a statin in the past 2 years and experienced statin-associated symptom in the past 6 months were included (N = 1500). Mean age was 58 years, 40.3% were men, and 43.2% had tried >= 2 statins. Many had clinical comorbidities associated with increased risk for cardiovascular disease (atherosclerotic cardiovascular disease, 22.5%; diabetes, 25.8%; hypertension, 56.0%). The most important patient-reported reasons for continuing current statin therapy (n = 1168; 77.9%) were avoiding a heart attack or stroke, lowering cholesterol, and doctor recommendation. Being bothered by and not being able to tolerate side effects were the main reasons respondents discontinued statins (n = 332; 22.1%). Respondents who discontinued statins reported significantly higher mean Symptom Severity (10.6 vs 8.7, P<.001) and Impact Severity scores (11.8 vs 9.8, P<.001) compared with those who continued. The STatin Adverse Treatment Experience survey highlights the importance of patients’ adverse experiences with statins and how symptom and impact scores affect decisions to continue or discontinue therapy.”

According to the news reporters, the research concluded: “These data provide a foundation to increase providers’ awareness of statin tolerability from the patient’s perspective and encourage benefit-risk discussions.”

For more information on this research see: The Statin Adverse Treatment Experience Survey: Experience of Patients Reporting Side Effects of Statin Therapy. Journal of Clinical Lipidology, 2019;13(3):415-424. Journal of Clinical Lipidology can be contacted at: Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA. (Elsevier - www.elsevier.com; Journal of Clinical Lipidology - http://www.journals.elsevier.com/journal-of-clinical-lipidology/)

Our news correspondents report that additional information may be obtained by contacting T.A. Jacobson, National Lipid Association, Hlth Qual & Res Comm, Jacksonville, FL, United States. Additional authors for this research include M.K. Cheeley, P.H. Jones, R. La Forge, K.C. Maki, J.D. Cohen, J.A.G. Lopez and P. Xiang.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jacl.2019.04.011. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright © 2019 NewsRx LLC, Disease Prevention Daily, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
08/14AMGEN : Board of Directors Tours Company Labs in San Francisco
PU
08/14AMGEN : Foundation Honors David Baltimore With Gift to Caltech
PU
08/14AMGEN : Ex-dividend day for
FA
08/12Health Care Down, But Losses Limited by Lack of Cyclical Exposure -- Health C..
DJ
08/12Amgen and Sysco rise while Viacom and Bank of America fall
AQ
08/12NOVARTIS : Sandoz will appeal District Court of New Jersey ruling in biosimilar ..
AQ
08/12AMGEN : Wins Patent Case on Enbrel
AQ
08/09Wall Street ends down amid more trade woes, high volatility
RE
08/09Canada enacts drug price crackdown, in blow to pharmaceutical industry
RE
08/09AMGEN : Wins Patent Case On Enbrel® (etanercept)
PR
More news
Financials (USD)
Sales 2019 22 830 M
EBIT 2019 10 915 M
Net income 2019 7 711 M
Debt 2019 2 336 M
Yield 2019 2,81%
P/E ratio 2019 16,2x
P/E ratio 2020 15,2x
EV / Sales2019 5,51x
EV / Sales2020 5,31x
Capitalization 124 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 209,76  $
Last Close Price 206,00  $
Spread / Highest target 12,1%
Spread / Average Target 1,83%
Spread / Lowest Target -16,0%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
David M. Reese Executive Vice President-Research & Development
Frank C. Herringer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN5.82%123 538
JOHNSON & JOHNSON2.48%349 030
ROCHE HOLDING LTD.12.24%239 457
ROCHE HOLDING13.20%239 457
MERCK AND COMPANY12.80%220 679
NOVARTIS17.81%205 341